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Somatic reversions of inherited mutations in adenosine 
deaminase deficiency, X-linked severe combined 
immunodeficiency (X-SCID), and Wiskott-Aldrich 
syndrome have been recognized in humans. These 
reversions are caused by either back mutations, with 
restoration of wild-type sequence, or second-site 
mutations, leading to compensatory changes. These 
mutations have been associated with milder clinical 
phenotypes in these primary T cell immunodeficiencies. 
Leukocyte adhesion deficiency Type I (LAD-I) is an 
autosomal recessive immunodeficiency affecting leuko- 
cyte adhesion caused by heterogeneous mutations in the 
PZ integrin, CDlS.These mutations prevent for mation 
of CDllKD18 heterodimers and surface expression of 
the receptor complex. Defective or absent CD18 on 
leukocytes, particularly neutrophils, leads to defective 
adherence to the endothelium and failure to migrate to 
the site of infection. 
Three moderately affected LAD-l patients were 
studied by flow cytometry. As expected, neutrophil CD18 
expression was markedly and homogeneously diminished 
compared to normals. However, we were surprised to 
find that each of these patients had a small subset of 
lymphocytes with normal CD18 expression (CD18+). 
These CD18+ lymphocytes were CD3+/CD8+/CD57+, 
representing potential cytotoxic T cells (CTL). 
CD3+/CD18+ and CD3+/CD18- lymphocytes from 
each patient were sorted using FACS Vantage (Becton- 
Dickinson) and genomic DNA was obtained. Micro- 
satellite analysis proved patient origin of CD18+ cells 
in each case. Subcloning and sequencing showed 
heterozygous reversion mutations in patients 1 and 2, 
and back mutation on one of patient 3’s alleles leading 
to correction of his splicing defect (Table).Although the 
reversions in patient 1 and 2 are not to the exact wild 
type (wt), but to a third amino acid, they support LFA- 
1 expression, and the expressed LFA-1 behaves like wt. 
Somatic reversions conferring CD18+ expression in 
these patients were detected primarily in CD3+/CD8+/ 
CD57+ cells. This suggests that somatic revertant 
CD18+ CTLs may have a survival advantage in LAD-l. 
Whether these revertant CD18+ CTL confer advantages 
on the host ameliorating disease awaits ongoing func- 
tional studies. The identification of 3 cases of reversion 
mutations in moderate LAD-l at one center suggests 
Patient No.1 
Age, Sex 
Patient 1 19y M 
Patient 2 22y F 
Patient 3 31y M 
Mutation 
Nucleotide: 
amino acid 
A392C: Y131S 
G850A: G2845 
A1052G: N3515 and 
C-A-1 2 741: 247+ PSSQ 
Patient No./ 
Age, Sex 
Patient 1 19y M 
Patient 2 22y F 
Patient 3 31y M 
Reversion % CD78+ 
Amino acid change lymphocytes 
Y131F 5 
G284R 7 
20 
C-12 741: 2474 
that this may be a relatively common event in this rare 
disease. Finally, this is the first identified series for 
somatic reversion in a primary phagocyte defect. 
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Background: Genetic susceptibility factors have been 
recognized to play a critical role in otherwise healthy 
individuals who develop disseminated nontuberculous 
mycobacterial (DNTM) infections. Exonic and intronic 
mutations in the interferon-y receptor 1 (IFNGRl) gene 
are among them. In contrast, no inherited susceptibility 
factors have been yet associated with pulmonary non- 
tuberculous mycobacterial (PNTM) infections. 
Methods: We sequenced the IFNGRl minimal promoter 
region (MPR) of 55 Caucasian patients with NTM in- 
fections, 17 disseminated and 38 pulmonary. No patients 
with known susceptibility factors to NTM were included. 
We also sequenced 86 Caucasian controls. We compared 
single nucleotide polymorphisms (SNPs) and inferred 
haplotype distributions between populations. 
Findings: We identified 10 previously undescribed 
SNPs in the IFNGRl MPR, two of which show strong 
statistical association with NTM infections in patients 
without other risk factors. Compared to controls, the 
polymorphisms -6llA and -56C were significantly over- 
represented in patients with DNTM infections (p=O.O04 
and 0.03, respectively), whereas polymorphism -6llA 
was significantly over-represented in patients with 
PNTM infections @=O.OOOl).The probability of finding 
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both polymorphisms (-6llA and -56C) was significantly 
higher in DNTM patients than in controls (OR= 16.8, CI 
95%=2.1-132) or in PNTM patients (OR=9.3, CI 
95 % = l.l-78.1).The probability of finding polymorphism 
-6llA in PNTM was higher than in controls (OR=8.4, 
CI 95%=2.4-29.4) but not different than in DNTM 
(OR=1.3, CI 95%=0.1-14). The inferred haplotypes 
also showed a skewed distribution: DNTM vs. controls, 
p=O.Ol; PNTM vs. controls, p=O.O006; and DNTM vs. 
PNTM,p=0.0013. 
1nterpretation:Tbe IFNGRl MPR is highly polymorphic 
and some of these polymorphisms are significantly 
associated with nontuberculous mycobacterial infections. 
This is the first study in which common genetic suscepti- 
bility factors have been associated with both disseminated 
and pulmonary NTM infections. 
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Background:The human toll-like receptor (TLR) family 
plays crucial roles in both the innate and adaptive 
immune systems, Among the 10 TLRs identified, TLR2 
mediates responses to Gram-positive bacteria, including 
mycobacteria. We sought functional polymorphisms in 
the promoter region of TLR2. 
Methods: Using direct sequencing of PCR fragments 
as well as PCR fragment sizing we found a highly 
polymorphic (GT)n dinucleotide repeat around 120 bp 
upstream of the TLR2 translational start site. We 
examined the distribution of each allele in normal donors 
of African (n=106), Caucasian (n=88) and Korean 
(n=98) descent. To further understand the functional 
implications of these polymorphisms, we fused the 1.5 kb 
of upstream TLR2 containing different lengths of GT 
repeat to luciferase and examined these in transient 
transfection under different stimulation conditions. 
Results: The numbers of GT repeats varied from 12 
to 28, with significant differences in allele distribution 
between African Americans and Caucasians (p =0.008) 
and between African Americans and Koreans 
(p=O.O003). The promoter activity of the longer alleles 
[(GT)n 2201 was significantly more inhibited by 200 
IU/ml of interferon-y (p=O.O02) than shorter alleles. 
Interestingly, this inhibition was not observed with 100 
IU/ml of GM-CSF. Genotypes consisting of [(GT)n 
1201 repeats were more prevalent in patients with 
disseminated nontuberculous mycobacterial infection 
(49%) than in normal controls (24%,p=O.O04). 
Interpretation: Given that TLR2 is critical in the human 
immune response against invading organisms, functional 
microsatellite polymorphisms in its promoter may play 
a role in the pathogenesis of infectious and inflammatory 
diseases, This particular TLR2 promoter polymorphism 
is significantly different according to race, appears to 
be disease associated, and is functionally important and 
discriminating in terms of in vitro response to interferon- 
y, a cytokine critical to the integrity of inflammation. 
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Epstein-Barr virus (EBV) is associated with a deadly 
complication in organ transplantation, the so-called 
posttransplant lymphoproliferative disorders (PTLD). 
Mismatched EBV-seronegative recipients and sero- 
positive donors represent an important risk factor. The 
management of PTLD is difficult and an interesting 
preventive strategy would be to immunize the recipients 
before transplantation.The peptide-based vaccination is 
advantageous because of the absence of genetic material 
and its easiness to be manufactured. Nevertheless human 
leukocyte antigen (HLA) polymorphism in humans is a 
major obstacle to consider. One of the critical aspects to 
design such vaccine is to select a synthetic peptide that 
would be restricted by common HLA alleles and then 
would be available for more individuals such as EBV- 
seronegative ones. 
Objectives: Our main objectives were to evaluate the 
capacity of a synthetic peptide corresponding to EBNA2 
to induce specific T cells in vitro, to determine which 
HLA alleles restricted this epitope, and finally to study 
the reactivity of the specific peptide-induced T cells. 
Methods: We obtained peripheral blood mononuclear 
cells (PBMCs) from ten healthy donors. Then using the 
peptide TVFYNIPPMPL, we induced all these donors to 
select the best responders by proliferation assays. Using 
specific antibodies and HLA-known cells lines, we 
attempted to determine the HLA alleles for this epitope. 
Finally, after positively selected CD4+ cells from the 
best reactive T cell lines, we measured by flowcytometry 
their capacity to inhibit B cell transformation. 
Results: EBV positive serology was confirmed for 6 out 
of the 10 donors. From these latter, 60% shows specific 
T cell response to EBNA2 peptide and these were 
mostly CD4+ T helpers. We found these T cells epitope 
HLA-DR restricted for 5 donors (HLA-DRl: -DR16, - 
